Valuation: Moderna, Inc.

Market Cap 29.28B 25.62B 23.62B 21.86B 41.49B 2,795B 42.18B 283B 111B 1,373B 110B 108B 4,754B P/E 2026 *
-8.84x
P/E 2027 * -16.1x
Enterprise Value 25.88B 22.64B 20.88B 19.31B 36.66B 2,470B 37.27B 250B 98B 1,213B 97.14B 95.04B 4,201B EV / Sales 2026 *
12.4x
EV / Sales 2027 * 10.7x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Moderna, Inc.

1 day+3.74%
1 week+5.60%
Current month+9.32%
1 month+60.84%
3 months+46.95%
6 months+126.11%
Current year+159.61%
1 week 73.14
Extreme 73.14
85.6
1 month 45.67
Extreme 45.67
85.6
Current year 29.81
Extreme 29.81
85.6
1 year 22.28
Extreme 22.28
85.6
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2011
Director of Finance/CFO 49 06/09/2022
President 50 01/11/2024
Director TitleAgeSince
Chairman 63 01/02/2012
Director/Board Member 54 01/03/2011
Director/Board Member 69 11/12/2019
Date Insider Type Main position Quantity % Market Cap.
07-05Free

Executive/Senior Manager

57,022 0.0144%
07-02Fiscal year

Chief Financial Officer

3,607 0.0009%
06-15Fiscal year

Chairperson

160,008 0.0403%
Change 5-day change 1-year change 3-year change Capi.($)
+3.74%+5.60%+135.28%-35.59% 29.28B
+0.76%+6.92%+21.94%-3.54% 67.44B
+0.52%-3.06%+46.97%+219.12% 53.98B
-2.79%+32.50%+32.50%+32.50% 41.77B
+0.99%+6.05%-48.96%-52.97% 41.15B
-0.72%-5.16%+47.93%-27.69% 29.58B
+1.07%+4.14%+75.14%+90.95% 23.43B
+0.17%+8.48%+4.86%+185.45% 19.11B
+1.14%+2.26%+68.00%+135.40% 16.82B
+15.12%+21.00%+108.78%+433.87% 15.36B
Average +2.00%+1.68%+49.24%+97.75% 33.79B
Weighted average by Cap. +1.10%+1.23%+39.67%+69.60%

Financials

2026 *2027 *
Net sales 2.09B 1.83B 1.69B 1.56B 2.97B 200B 3.02B 20.23B 7.93B 98.13B 7.86B 7.69B 340B 2.55B 2.23B 2.06B 1.9B 3.61B 243B 3.67B 24.63B 9.66B 120B 9.57B 9.37B 414B
Net income -3.41B -2.98B -2.75B -2.55B -4.83B -326B -4.91B -32.95B -12.92B -160B -12.8B -12.53B -554B -1.85B -1.62B -1.49B -1.38B -2.62B -177B -2.67B -17.87B -7.01B -86.72B -6.95B -6.8B -300B
Net Debt -3.41B -2.98B -2.75B -2.54B -4.83B -325B -4.91B -32.9B -12.9B -160B -12.79B -12.51B -553B -2.05B -1.8B -1.66B -1.53B -2.91B -196B -2.96B -19.84B -7.78B -96.24B -7.71B -7.54B -333B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
09/07/26 $76.56 +3.74% 4,338,079
08/07/26 $73.80 -7.48% 6,581,662
07/07/26 $79.77 -2.48% 8,688,340
06/07/26 $81.80 +2.56% 17,296,875
02/07/26 $79.76 +10.01% 14,111,998
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
73.80USD
Average target price
47.89USD
Spread / Average Target
-35.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock